A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.

Feng S, Zhang Y, Hou C, Liu Y, Gao Y, Song Y, Luo J

Science advances28 Aug 2024Cited by 8 (Europe PMC)

PMID39196940PMCIDPMC11352908DOI10.1126/sciadv.adn8695PepBankPUB-39196940

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

01AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Pharmacokinetics
In the delivery study, insulin-pramlintide HormFoam enhanced intestinal drug distribution after rectal administration.
In plain wordsIn mice, insulin-pramlintide HormFoam enhanced intestinal drug distribution after rectal administration.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseIntestinal distribution
Study
mousen: not reported in source
diabetic mice
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
We found that HormFoam could consistently generate foams to drive drugs forward after rectal administration, which enhanced intestinal distribution and mucosa absorption, leading to systemic codelivery of insulin-pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
To support rapid clinical translation, a continuous microfluidic preparation for HormFoam was proposed, including the power unit of perfluorocarbon nanodroplets and the pharmaceutical components Pluronic F127-functionalized liposomal insulin and pramlintide.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3919694001
02AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Pharmacokinetics
In the delivery study, insulin-pramlintide HormFoam enhanced mucosal absorption after rectal administration.
In plain wordsIn mice, insulin-pramlintide HormFoam enhanced mucosal absorption after rectal administration.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseMucosal absorption
Study
mousen: not reported in source
diabetic mice
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
We found that HormFoam could consistently generate foams to drive drugs forward after rectal administration, which enhanced intestinal distribution and mucosa absorption, leading to systemic codelivery of insulin-pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
To support rapid clinical translation, a continuous microfluidic preparation for HormFoam was proposed, including the power unit of perfluorocarbon nanodroplets and the pharmaceutical components Pluronic F127-functionalized liposomal insulin and pramlintide.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3919694002
03AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, insulin-pramlintide HormFoam controlled glycemia, induced weight loss, and reversed metabolic disorders.
In plain wordsIn mice with diabetes, insulin-pramlintide HormFoam controlled blood sugar, reduced weight, and reversed metabolic disorders.
Peptide
Pramlintide (Symlin)
Outcome
MixedMetabolic control and body weight
Study
mousen: not reported in source
diabetic mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
HormFoam reproduced the physiology of endocrine pancreas for glycemic control and induced body weight loss while reversing metabolic disorders in diabetic mice with good biosafety.
1 context sentence(design, population, supporting numbers)
Summary · context
To support rapid clinical translation, a continuous microfluidic preparation for HormFoam was proposed, including the power unit of perfluorocarbon nanodroplets and the pharmaceutical components Pluronic F127-functionalized liposomal insulin and pramlintide.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3919694003
04AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Safety outcome
In diabetic mice, insulin-pramlintide HormFoam showed good biosafety without specific safety measures reported.
In plain wordsIn mice with diabetes, insulin-pramlintide HormFoam showed good biosafety, but the abstract gives no specific safety measures.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableBiosafety
Study
mousen: not reported in source
diabetic mice
Outcome group
Adverse events · Whole body
Source sentences
Summary
HormFoam reproduced the physiology of endocrine pancreas for glycemic control and induced body weight loss while reversing metabolic disorders in diabetic mice with good biosafety.
1 context sentence(design, population, supporting numbers)
Summary · context
To support rapid clinical translation, a continuous microfluidic preparation for HormFoam was proposed, including the power unit of perfluorocarbon nanodroplets and the pharmaceutical components Pluronic F127-functionalized liposomal insulin and pramlintide.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3919694004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.